Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Takeda Pharmaceutical Company Limited American Depositary Shares (each (NY:TAK)

14.72 -0.47 (-3.09%)
Official Closing Price Updated: 7:00 PM EDT, Apr 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Takeda Pharmaceutical Company Limited American Depositary Shares (each

< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
17 18 Next >
Takeda’s TAKHZYRO® (lanadelumab) Demonstrated Positive Results in the Prevention of HAE Attacks in First and Only Open-Label Phase 3 Trial in Children Ages 2 to <12 Years
From Takeda Pharmaceutical Company Limited
Via Business Wire
Results from Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency Published in New England Journal of Medicine
From Takeda Pharmaceutical Company Limited
Via Business Wire
Takeda Pharma Clocks 1% Increase In FY21 Core Profit, Expects Growth Momentum In FY22
Via Benzinga
Takeda Announces Creation of One Cambridge Campus in Kendall Square to Drive Innovation Efforts
From Takeda Pharmaceutical Company Limited
Via Business Wire
As Health Problems Mount Patients Welcome New Treatments
Palm Beach, FL – June 14, 2022 – FinancialNewsMedia.com News Commentary – There are several serious health problems facing society today. Some, like heart disease, gastrointestinal diseases, cancer,... 
Via FinancialNewsMedia
Takeda’s Dengue Vaccine Candidate Provides Continued Protection Against Dengue Fever Through 4.5 Years in Pivotal Clinical Trial
From Takeda Pharmaceutical Company Limited
Via Business Wire
Moderna Pops On Updated Booster Data, But Analyst Says It Needs A 'Second Act'
Moderna tested a bivalent booster, which targets two Covid strains in one shot. 
Via Investor's Business Daily
Quant Ratings Updated on 66 Stocks
Out of the 66 stocks that were upgraded/downgraded this weekend, 12 were downgraded to a D-rating. And I'm giving you the first 10. 
Via InvestorPlace
Takeda Presents Latest Research from Oncology Portfolio and Pipeline at ASCO & EHA
From Takeda Pharmaceutical Company Limited
Via Business Wire
Takeda and Moderna Announce Plans to Transfer Marketing Authorization for Spikevax™ COVID-19 Vaccine in Japan to Moderna
From Takeda Pharmaceutical Company Limited
Via Business Wire
Moderna and Takeda Announce Plans to Transfer Marketing Authorization for Spikevax(TM) COVID-19 Vaccine in Japan to Moderna
Moderna to become marketing authorization holder in Japan and be responsible for all import, local regulatory, development, quality assurance, and commercial activities for SpikevaxTM from August 1,... 
From Moderna, Inc.
Via AccessWire
Exposures COVID-19
Takeda and Seagen to Highlight ADCETRIS® Combination Data Showing Statistically Significant Improvement in Overall Survival (OS) for Patients with Advanced Hodgkin Lymphoma
From Takeda Pharmaceutical Company Limited
Via Business Wire
Current Report: Takeda Pharmaceutical
Takeda’s price per share was $14.31 as of yesterday's market close. One year ago its price was $17.20. 
Via Talk Markets
Takeda Delivers Strong FY2021 Results; Continued Growth Momentum Expected in FY2022
From Takeda Pharmaceutical Company Limited
Via Business Wire
Takeda Recognized as the 2022 ISPE Facility of the Year Awards Winner in Two Categories
From Takeda Pharmaceutical Company Limited
Via Business Wire
Takeda's Maribavir Reduces Hospitalization Rates, Hospital Stay In Post-Transplant Infection Patients
Via Benzinga
Takeda Presents New Exploratory Analysis Showing Patients Treated With LIVTENCITY™ (Maribavir) Had Reductions in Hospitalization Rates and Length of Hospital Stay
From Takeda Pharmaceutical Company Limited
Via Business Wire
Novavax Stock Looks Like a Good Value With Its New Combined Vaccine
NVAX stock could be worth 63% more based on its new combination flu and Covid-19 vaccine after passing Phase 1/2 clinical trials. 
Via InvestorPlace
Takeda Announces Approval of Nuvaxovid® COVID-19 Vaccine for Primary and Booster Immunization in Japan
From Takeda Pharmaceutical Company Limited
Via Business Wire
Japan's Health Ministry Panel OKs Approval Of Novavax's COVID-19 Vaccine: Report
Via Benzinga
Takeda’s TAKHZYRO® (lanadelumab-flyo) Prefilled Syringe Now Available for People With Hereditary Angioedema (HAE) Ages 12 Years and Older in the United States
From Takeda Pharmaceutical Company Limited
Via Business Wire
Phathom Pharma's Vonoprazan Commercial Preparation Update At Needham Healthcare Conference
Via Benzinga
Cognitive Drugs Market Expected Reach Revenues Of $21 Billion in 2027
Palm Beach, FL – April 13, 2022 – FinancialNewsMedia.com News Commentary – Dementia is the loss of cognitive functioning, thinking, remembering, reasoning, and behavioral abilities to such an extent... 
Via FinancialNewsMedia
Exposures COVID-19
Takeda Announces Completion of Acquisition of Own Shares
From Takeda Pharmaceutical Company Limited
Via Business Wire
The Daily Biotech Pulse: Aeglea Stock Jumps On Inherited Metabolic Disease Data, Partial Hold Lifted On Gilead's 2 Blood Trials, Early Data From Novartis' KRAS Inhibitor And More
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Takeda’s TAKHZYRO® (lanadelumab) Open Label Phase 3 Study Met Its Objectives in Children Ages 2 to <12 Years of Age With Hereditary Angioedema (HAE)
From Takeda Pharmaceutical Company Limited
Via Business Wire
Takeda and the New York Academy of Sciences Announce 2022 Innovators in Science Award Winners
From Takeda Pharmaceutical Company Limited
Via Business Wire
Monday Markets News
Japanese Takeda TAK shares failed to thrive after its edema prevention drug was approved. 
Via Talk Markets
Takeda’s TAKHZYRO® (lanadelumab) Approved in Japan for Prophylaxis Against Acute Attacks of Hereditary Angioedema (HAE)
From Takeda Pharmaceutical Company Limited
Via Business Wire
Takeda's Angioedema Drug Shows Promising Action Against COVID-19 Infection
Takeda Pharmaceutical Co Ltd's (NYSE: TAK) Firazyr (icatibant), used to treat a blood vessel condition called angioedema, has shown promise as a treatment for COVID... 
Via Benzinga
< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
17 18 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.